Skip to main content
OpenTrials
Completed

NCT Number: NCT00232050

Study of Omalizumab in Moderate to Severe Bronchial Asthma

This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Epilepsy, Idiopathic Generalized Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

20 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Allergic asthma patients
  • Inadequately controlled patients

Exclusion criteria

  • - History of severe anaphylactoid or anaphylactic reactions
  • Previous treatment with omalizumab
  • History of cancer or cancer

Other protocol-defined exclusion criteria may apply

Treatment and study plan

Omalizumab

Drug

Primary outcomes

  1. Morning peak expiratory flow (PEF) at baseline and end of treatment.

Secondary outcomes

  1. Pulmonary function parameters measured by spirometer

  2. Frequency of rescue medication use

  3. Symptom score

  4. Activities of daily living score

  5. Nighttime sleep score

Sponsors and collaborators

Lead sponsor

Novartis

Industry

Collaborators

  • Daiichi Sankyo Co., Ltd.

Registry information

Important dates

Study start
2002
Primary completion
2005
Study completion
2005
First posted
Oct 4, 2005
Registry last updated
Oct 25, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.